Connect your AI

Artiva Biotherapeutics, Inc. ARTV PP&E (Net)

PP&E (Net) at other companies

Bristol-Myers SquibbBMY

$7.66B+6.2%

Gilead SciencesGILD

$5.64B+4.0%

Kyverna Therapeutics, Inc.KYTX

$1.34M-44.9%

Allogene TherapeuticsALLO

$70.02M-15.6%

Immix Biopharma, Inc.IMMX

$2.43M+14.3%

ImmunityBio, Inc.IBRX

$112.79M-16.6%

Other financials

Income statement

Revenue-—

Operating income-$24.4M-10.2%

Net income-$23.5M-15.8%

EPS (diluted)-$0.95-14.5%

Balance sheet

Cash & equivalents$21.4M-30.6%

Total debt$10.3M-26.7%

Total equity$87.8M-48.0%

Total assets$106.0M-44.6%

Cash flow

Operating cash flow-$21.0M-5.6%

CapEx$242.0K-52.6%

Free cash flow-$21.2M-4.1%

Valuation

Market cap$429.03M+1,015%

Enterprise value$417.88M+1,832%

Profitability

Operating margin-83.9%—

Net margin-79.3%—

Returns & leverage

Return on equity-67.9%—

Debt / equity0.1×0.0×

Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s PP&E (net)?: Artiva Biotherapeutics, Inc. (ARTV) reported PP&E (net) of $6.22M in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s PP&E (net) changed year-over-year?: Artiva Biotherapeutics, Inc.'s PP&E (net) decreased by 11.9% year-over-year, from $7.06M to $6.22M.
What is the long-term trend for Artiva Biotherapeutics, Inc.'s PP&E (net)?: Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s PP&E (net) has grown at a -9.6% compound annual growth rate (CAGR), from $8.1M to $6.62M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.